Mode
Text Size
Log in / Sign up
N/A Completed N=89 Randomized Double-blind Treatment

Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)

Source: ClinicalTrials.gov NCT02086448 ↗
Enrolled (actual)
89
Serious AEs
2.3%
Results posted
Mar 2022
Primary outcomePrimary: Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound — 1.0; 1.0; 1.0; 1.0 Mean PI

Summary

The purpose of this study is to better understand how sleep apnea, a common sleep disorder in which a person has one or more pauses in breathing or shallow breaths while sleeping, may affect pregnancy and to determine the effect of Continuous Positive Airway Pressure (CPAP), a treatment that uses mild air pressure to keep the airways open during sleep, for pregnant women with sleep apnea.

Outcome Measures

OutcomeResultp-value
PRIMARY
Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound
0.9; 0.8; 0.8; 0.7
PRIMARY
Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement
30.5; 26.0; 38.3; 45.9
PRIMARY
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin
6.3; 3.7; 3.6; 4.6
SECONDARY
Placental Histology and Immunohistochemistry

Eligibility Criteria

Inclusion Criteria

  • women between 14 0/7 and 20 6/7 weeks gestation at the time of their initial PSG assessment.
  • Pregnancy and current BMI >=30
  • Self-reported frequent snoring (>=3x/week over past month) or self-reported non-snorer.

Exclusion Criteria

  • diagnosis of pregestational diabetes.
  • self-report a history of sleep apena and who are using or were receommended by a physican to use a PAP device already
  • twins
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02086448). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search